AbCellera Reports Q1 2025 Financial Results and New Antibody

AbCellera Biologics ( (ABCL) ) has shared an announcement.

On May 8, 2025, AbCellera Biologics announced its financial results for the first quarter of 2025, reporting a total revenue of $4.2 million and a net loss of $45.6 million. The company highlighted the introduction of ABCL635, a potential first-in-class antibody for treating menopause-related vasomotor symptoms, with plans to start Phase 1 clinical trials in the latter half of 2025. Despite the financial loss, AbCellera maintained significant liquidity of over $800 million to support its strategic initiatives, including 97 partner-initiated programs and 16 molecules reaching the clinic.

Spark’s Take on ABCL Stock

According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.

AbCellera Biologics’ overall stock score is impacted by significant financial challenges, particularly in income and cash flow management, and negative valuation metrics. While technical indicators suggest some positive momentum, the company’s strategic transition to a clinical-stage biotech and strong liquidity offer potential, albeit with risks due to high R&D expenses and declining revenues.

To see Spark’s full report on ABCL stock, click here.

More about AbCellera Biologics

AbCellera Biologics Inc. is a company that discovers and develops antibody medicines for various therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. The company integrates technology, data science, and interdisciplinary teams to solve complex antibody discovery challenges and focuses on advancing both internal and collaborative drug development programs.

Average Trading Volume: 4,226,538

Technical Sentiment Signal: Sell

Current Market Cap: $604.9M

Find detailed analytics on ABCL stock on TipRanks’ Stock Analysis page.